Navigation Links
CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenue Increase
Date:10/9/2008

mbination of a 12% increase in third quarter ICG device sales along with a 10% increase in the average unit sales price of our ICG Monitors compared with the third quarter of 2007. This increase in average unit selling price is principally due to a proportionately greater number of higher priced BioZ Dx systems sold during the third quarter of 2008, as compared to the third quarter of 2007 and lower sales return reserve requirements.

Gross margin as a percentage of sales increased from 72% to 75% in the third quarter of 2008, largely due to a 10% average unit sales price improvement, lower inventory reserve requirements, reduced manufacturing overhead costs, and a reduction of sales returns reserve.

Operating expenses were reduced 8% (or $398,000) to $4.8 million, driven primarily by improved efficiencies, reduced personnel expenses, lower accounting fees and bad debt provisions, all part of an ongoing cost containment focus in support of the Company's plan to regain profitability.

The operating loss improved 78% to $254,000, compared to an operating loss of $1.2 million for the same period in 2007. The year-to-date operating loss was $1.6 million, a 61% improvement from $4.0 million in the same nine month period of 2007.

CEO Comments and Outlook

Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "We were very pleased with our performance in the third quarter, particularly the rate of improvement we are making in reducing the operating loss. Excluding non-cash expenses for depreciation, amortization and stock option compensation, we experienced positive income from operations for the first time in 15 quarters and one quarter ahead of plan. Achieving our seventh consecutive quarterly year-over-year revenue growth and 15% growth year-to-date is encouraging and a testament to the continued growth potential for ICG."

Perry continued, "Our goal remains to achieve positive operating cash flow in the fourth quarte
'/>"/>

SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CardioDynamics BioZ(R) ICG Technology Integrates with General Electric Healthcares Centricity(R) Electronic Medical Record (EMR) System
2. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
3. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
4. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
5. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
6. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. Corgenix Reports Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015  Health eCareers, ... short-staffed healthcare organizations with job seekers looking for ... , a new mobile and online tool dedicated ... healthcare industry. SHIFT enables employers to ... tenens, travel nursing, per diem and other temporary ...
(Date:5/20/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) announced ... will present at The Jefferies 2015 Global Healthcare Conference ... 1 st , 2015 at 8:30am Eastern time.  ... live via webcast at: http://wsw.com/webcast/jeff88/hae ... ) is a global healthcare company dedicated to providing ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdsx2f/bone ... "Bone Morphogenetic Proteins Market (Types : rhBMP-2 and ... - Maxillofacial) - Global Industry Analysis, Size, Share, ... report to their offering. The global ... the types of recombinant BMPs, applications, and geography. ...
(Date:5/20/2015)... The Greater Gift Initiative, Inc ... pleased to announce they are donating 10,010 vaccines today ... represent the effort and commitment of clinical trial volunteers ... sites in 2014. , With a mission to ... clinical trial participation, GGI supports International Clinical Trials Day ...
Breaking Biology Technology:Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
... ... 2008 -- Facilitating the entry of Bluetooth into the ... effortlessly examine not only the wireless interface between devices, such as ... between the device CPU and the Bluetooth chip inside the device. ...
... SEATTLE, Dec. 16 The Washington Life Sciences Discovery,Fund ... start-up phase of,the Washington Vaccine Alliance (WAVA) and to ... herpes and syphilis. Announced today, the,grant is funded by ... this innovative new organization to,life. , ...
... Colo.,Dec. 16 Bolder BioTechnology, Inc. today announced that ... Small Business Innovation Research (SBIR) grant from the National ... National Institutes of Health (NIH). The grant will ... studies of the company,s proprietary long-acting growth hormone product, ...
Cached Biology Technology:Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 2Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 4Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product 2
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/6/2015)... Israel , May 6, 2015 LifeBEAM, ... most established helmet producer, announced today that they will ... Helmet, the world,s first bio-sensing cycling helmet and the ... released in two new colors in order to give ... the product. In addition, LifeBEAM and Lazer announced their ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... to be a godsend for many of the two ... its downside. People on the drug may develop hypothyroidism, ... gain weight. , However, better treatments for bipolar disorder ... by which lithium damps the highs and lows of ...
... they see colors when viewing letters and numbers really ... of the University of California San Diego, have found. ... brains reveals that they show activation of color-perception areas. ... the hypothesis that the condition is due to cross-activation ...
... have found a way of stimulating the immune ... cause the devastating plaques,that are characteristic of Alzheimer's ... using a,protein-based vaccine to slow the progression of ... have created a gene-based,vaccine aimed at stimulating the ...
Cached Biology News:Beyond lithium for bipolar disorder 2New insight into people who 'see' colors in letters and numbers 2Gene vaccine for Alzheimer's disease shows promising results 2
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
...
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
Request Info...
Biology Products: